Study outcome won't sway company on eye drug

August 27th, 2008 in Medicine & Health / Other

(AP) -- What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000? In the case of Genentech Inc., nothing.

---

Content from The Associated Press expires 15 days after original publication date. For more information about The Associated Press, please visit www.ap.org .

---